A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.
Also called NCT05275400
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 986 participants
- Sponsor
- Registry
-
NCT05275400 -
2021-002569-16
-
- Other papers using this trial's data
- Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Hungary, Japan, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05275400. Randomized; no masking; primary purpose treatment. Start 2022-03-08 (actual); primary completion 2024-05-15 (actual). Results posted on 2025-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin Efsitora Alfa
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05275400- Content hash
78ea0b5bd5dafd1b30a29de860bcb1d46b6e4bc2464e5418b1377c2c4202bf28